drugset / Trial / NCT01569074

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

NCT01569074

Phase 2 Terminated 163 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the effectiveness of four dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding. The study will last for 12 weeks.

Timeline

Start
2012-04
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 50 mg Oral
Subject Fostamatinib Small molecule 75 mg Oral
Subject Fostamatinib Small molecule 100 mg Oral
Subject Fostamatinib Small molecule 150 mg Oral

Indications